[Click eStock] "Jinwon Life Sciences, Competitor Sold for 11 Trillion... Still Undervalued"

[Asia Economy Reporter Jang Hyowon] Leading Investment & Securities analyzed on the 23rd that Jinwon Life Sciences is still significantly undervalued, considering that its subsidiary VGXI's competitor Aldevron was sold to Danaher for about $9.6 billion (approximately 11 trillion KRW).

Researcher Oh Seungtaek of Leading Investment & Securities explained, "The corporate value has increased about threefold from the approximately 4 trillion KRW valuation when EQT invested in Aldevron in 2019," adding, "This is evidence that the value of plasmid DNA production facilities is highly regarded by global investors."

According to Leading Investment & Securities, Aldevron's production facility is 189,000 square feet (ft²) in size, whereas Jinwon Life Sciences' currently under-construction production facility is 240,000 square feet (ft²), with plans to expand further to 540,000 square feet (ft²) by 2024.

Researcher Oh analyzed, "Even if some discount is applied to VGXI's value considering the management premium from Danaher's recent aggressive investments in the biotechnology sector, Jinwon Life Sciences' current market capitalization of 1.5 trillion KRW remains in a significantly undervalued range."

This content was produced with the assistance of AI translation services.